Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis

References

• Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294(5543):862-4
   PubMed Web of Science ®Google Scholar
• Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001;294(5543):858-62
   PubMed Web of Science ®Google Scholar
• Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009;285(2):116-26
   PubMed Web of Science ®Google Scholar
• Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009;13(1):39-53
   PubMed Web of Science ®Google Scholar
• Banzhaf-Strathmann J, Edbauer D. Good guy or bad guy: the opposing roles of microRNA 125b in cancer. Cell Commun Signal 2014;12:30
   PubMed Web of Science ®Google Scholar
• Ferracin M, Pedriali M, Veronese A, et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 2011;225(1):43-53
   PubMed Web of Science ®Google Scholar
• Meiri E, Mueller WC, Rosenwald S, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012;17(6):801-12
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014;11(3):145-56
   PubMed Web of Science ®Google Scholar
• Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108(12):5003-8
   PubMed Web of Science ®Google Scholar
• Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10(12):1470-6
   PubMed Web of Science ®Google Scholar
• Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13(4):423-33
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105(30):10513-18
   PubMed Web of Science ®Google Scholar
• Witwer KW. Circulating MicroRNA Biomarker Studies: Pitfalls and Potential Solutions. Clin Chem 2015;61(1):56-63
   PubMed Web of Science ®Google Scholar
• Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010;10(3):297-308
   PubMed Web of Science ®Google Scholar
• Cancer genome atlas. Available from: http://cancergenome.nih.gov
   Google Scholar
• Cancer genome atlas. Available from: https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp
   Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2(5):401-4
   PubMed Web of Science ®Google Scholar
• Fire browse. Available from: http://firebrowse.org/
   Google Scholar
• Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499(7456):43-9
   PubMed Web of Science ®Google Scholar
• Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25
   PubMed Web of Science ®Google Scholar
• Integrated genomic analyses of ovarian carcinoma. Nature 2011;474(7353):609-15
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17(5):510-22
   PubMed Web of Science ®Google Scholar
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
   PubMed Web of Science ®Google Scholar
• Shi Y, Chen C, Zhang X, et al. Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin Cancer Res 2014;20(7):1803-13
   PubMed Web of Science ®Google Scholar
• Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013;23(2):186-99
   PubMed Web of Science ®Google Scholar
• Qiu S, Lin S, Hu D, et al. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med 2013;11:10
   PubMed Web of Science ®Google Scholar
• Christinat Y, Krek W. Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer. Oncotarget 2015;6(12):10521-31
   PubMedGoogle Scholar
• Meng W, Ye Z, Cui R, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res 2013;19(19):5423-33
   PubMed Web of Science ®Google Scholar
• Volinia S, Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A 2013;110(18):7413-17
   PubMed Web of Science ®Google Scholar
• Ryland GL, Bearfoot JL, Doyle MA, et al. MicroRNA genes and their target 3’-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS One 2012;7(4):e35805
   PubMed Web of Science ®Google Scholar
• Shen J, DiCioccio R, Odunsi K, et al. Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer 2010;10:47
   PubMed Web of Science ®Google Scholar
• Wang M, Chu H, Li P, et al. Genetic variants in miRNAs predict bladder cancer risk and recurrence. Cancer Res 2012;72(23):6173-82
   PubMed Web of Science ®Google Scholar
• Christensen BC, Avissar-Whiting M, Ouellet LG, et al. Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin Cancer Res 2010;16(14):3713-20
   PubMed Web of Science ®Google Scholar
• Kminkova J, Mraz M, Zaprazna K, et al. Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. Carcinogenesis 2014;35(5):992-1002
   PubMed Web of Science ®Google Scholar
• Iuliano R, Vismara MF, Dattilo V, et al. The role of microRNAs in cancer susceptibility. Biomed Res Int 2013;2013:591931
   PubMed Web of Science ®Google Scholar
• Stegeman S, Amankwah E, Klein K, et al. A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer. Cancer Discov 2015;5(4):368-79
   PubMed Web of Science ®Google Scholar
• Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141(5):672-5
   PubMed Web of Science ®Google Scholar
• Tiberio P, Callari M, Angeloni V, et al. Challenges in Using Circulating miRNAs as Cancer Biomarkers. Biomed Res Int 2015;2015:731479
   PubMed Web of Science ®Google Scholar
• Saikumar J, Ramachandran K, Vaidya VS. Noninvasive micromarkers. Clin Chem 2014;60(9):1158-73
   PubMed Web of Science ®Google Scholar
• Moldovan L, Batte KE, Trgovcich J, et al. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 2014;18(3):371-90
   PubMed Web of Science ®Google Scholar
• Jarry J, Schadendorf D, Greenwood C, et al. The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol 2014;8(4):819-29
   PubMed Web of Science ®Google Scholar
• Wang K, Yuan Y, Cho JH, et al. Comparing the MicroRNA spectrum between serum and plasma. PLoS One 2012;7(7):e41561
   PubMed Web of Science ®Google Scholar
• Cheng HH, Yi HS, Kim Y, et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One 2013;8(6):e64795
   PubMed Web of Science ®Google Scholar
• Cookson VJ, Bentley MA, Hogan BV, et al. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr) 2012;35(4):301-8
   Google Scholar
• Shin VY, Siu JM, Cheuk I, et al. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer 2015;112(11):1751-9
   PubMed Web of Science ®Google Scholar
• Kleivi Sahlberg K, Bottai G, Naume B, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res 2015;21(5):1207-14
   PubMed Web of Science ®Google Scholar
• Montani F, Marzi MJ, Dezi F, et al. miR-Test: A Blood Test for Lung Cancer Early Detection. J Natl Cancer Inst 2015;107(6):djvo63
   Web of Science ®Google Scholar
• Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014;32(8):768-73
   PubMed Web of Science ®Google Scholar
• Yang IP, Tsai HL, Huang CW, et al. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One 2013;8(6):e66842
   PubMed Web of Science ®Google Scholar
• Vega AB, Pericay C, Moya I, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep 2013;30(1):320-6
   PubMed Web of Science ®Google Scholar
• Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma MicroRNAs for early detection of colorectal cancer. PLoS One 2013;8(5):e62880
   PubMed Web of Science ®Google Scholar
• Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 2012;36(1):e61-7
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127(1):118-26
   PubMed Web of Science ®Google Scholar
• McDermott AM, Miller N, Wall D, et al. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS One 2014;9(1):e87032
   PubMed Web of Science ®Google Scholar
• Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. Int J Mol Med 2012;30(3):680-6
   PubMed Web of Science ®Google Scholar
• Ferracin M, Lupini L, Salamon I, et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget 2015;6(16):14545-55
   PubMedGoogle Scholar
• Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 2013;10(10):1003-5
   PubMed Web of Science ®Google Scholar
• Keller A, Leidinger P, Bauer A, et al. Toward the blood-borne miRNome of human diseases. Nat Methods 2011;8(10):841-3
   PubMed Web of Science ®Google Scholar
• Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311(4):392-404
   PubMed Web of Science ®Google Scholar
• Schrauder MG, Strick R, Schulz-Wendtland R, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 2012;7(1):e29770
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrialsregister.eu
   Google Scholar
• Protein quest. Available from: www.proteinquest.com
   Google Scholar
• Circulating miRNAs. ICORG 10-11, V2. Available from: https://clinicaltrials.gov/ct2/show/NCT01722851
   Google Scholar
• Evaluating the expression levels of microRNA-10b in patients with gliomas. Available from: https://clinicaltrials.gov/ct2/show/NCT01849952
   Google Scholar
• Efficacy of propranolol treatment to prevent melanoma progression. Available from: https://clinicaltrials.gov/ct2/show/NCT01988831
   Google Scholar
• Circulating microRNA as biomarker of cardiotoxicity in breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02065908
   Google Scholar
• Biomarkers to distinguish benign from malignant thyroid neoplasm. Available from: https://clinicaltrials.gov/ct2/show/NCT01433809
   Google Scholar
• Blood samples from patients with non-small cell lung cancer and from healthy volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT00897234
   Google Scholar
• Studying biomarkers in cell samples from patients with acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01057199
   Google Scholar
• Association between VEGF-C and miRNA and clinical non-small cell lung cancer and esophagus squamous cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01240369
   Google Scholar
• Biomarker study in samples from patients with malignant rhabdoid tumor of the kidney or atypical teratoid rhabdoid tumor. Available from: https://clinicaltrials.gov/ct2/show/NCT01453465
   Google Scholar
• Biomarkers in bone marrow samples from young patients with acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01298414
   Google Scholar
• Biomarkers in samples from patients with B-cell acute lymphoblastic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01505699
   Google Scholar
• Biomarkers in tissue samples from patients with stage I or stage III endometrial cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01119573
   Google Scholar
• Biomarkers in young patients with neuroblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01169376
   Google Scholar
• Quantifying microRNA levels of colon (CRC). Available from: https://clinicaltrials.gov/ct2/show/NCT01712958
   Google Scholar
• RNA biomarkers in tissue samples from infants with acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01229124
   Google Scholar
• Serial blood and urine monitoring study in kidney transplant recipients (PROGENI-KI). Available from: https://clinicaltrials.gov/ct2/show/NCT01289717
   Google Scholar
• Studying biomarker expression in samples from patients with down syndrome and acute myeloid leukemia or other transient myeloproliferative disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT01511575
   Google Scholar
• Studying genes in samples from younger patients with adrenocortical tumor. Available from: https://clinicaltrials.gov/ct2/show/NCT01528956
   Google Scholar
• Studying genes in samples from younger patients with ovarian or testicular sex cord stromal tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01572467
   Google Scholar
• Adipose tissue and polycystic ovary syndrome (PCOS) (EIFFEL). Available from: https://clinicaltrials.gov/ct2/show/NCT01745471
   Google Scholar
• Genetics study of tissue collected from patients with acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00898092
   Google Scholar
• Laboratory study of lymphoblasts in young patients with high-risk acute lymphoblastic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00896766
   Google Scholar
• Longitudinal study of biomarkers. Available from: https://clinicaltrials.gov/ct2/show/NCT01595126
   Google Scholar
• microRNA expression in renal cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00743054
   Google Scholar
• Study of specimens from young patients with neuroblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00958659
   Google Scholar
• Lenalidomide, cytarabine, and idarubicin in treating patients with acute myeloid leukemia. Available from: http://findclinicaltrials.us/trials/NCT01132586.html
   Google Scholar
• Trebananib with or without low-dose cytarabine in treating patients with acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01555268
   Google Scholar
• A Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01999972
   Google Scholar
• Biomarkers for the early diagnosis, prediction, prognosis for colorectal cancers. Available from: https://clinicaltrials.gov/ct2/show/NCT01828918
   Google Scholar
• Naproxen in preventing DNA mismatch repair deficient colorectal cancer in patients with lynch syndrome. Available from: https://clinicaltrials.gov/ct2/show/NCT02052908
   Google Scholar
• Study of hydroxychloroquine before surgery in patients with primary renal cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01144169
   Google Scholar
• Acetylsalicylic acid compared to placebo in treating high-risk patients with subsolid lung nodules. Available from: https://clinicaltrials.gov/ct2/show/NCT02169271
   Google Scholar
• Pralatrexate and oxaliplatin in treating patients with unresectable or metastatic esophageal, stomach, or gastroesophageal junction cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01178944
   Google Scholar
• Atu027 plus gemcitabine in advanced or metastatic pancreatic cancer (Atu027-I-02). Available from: https://clinicaltrials.gov/ct2/show/NCT01808638
   Google Scholar
• Chemotherapy and radiation therapy with or without panitumumab in treating patients with stage IIIA non-small cell lung cancer (Cetuximab Closed as of 05/14/10). Available from: https://clinicaltrials.gov/ct2/show/NCT00979212
   Google Scholar
• IMaging patients for cancer drug selection - metastatic breast cancer (IMPACT-MBC). Available from: https://clinicaltrials.gov/ct2/show/NCT01957332
   Google Scholar
• Preventative trial of DFMO in patients with high risk neuroblastoma in remission. Available from: https://clinicaltrials.gov/ct2/show/NCT01586260
   Google Scholar
• Quality of life study in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel (QOLINPAC). Available from: https://clinicaltrials.gov/ct2/show/NCT02106884
   Google Scholar
• Sequential therapy with bevacizumab, RAd001 (Everolimus) and tyrosinekinase inhibitors (TKI) in metastatic renal cell carinoma (mRCC) (BERAT). Available from: https://clinicaltrials.gov/ct2/show/NCT01731158
   Google Scholar
• Trimetazidine in pulmonary artery hypertension. Available from: https://clinicaltrials.gov/ct2/show/NCT02102672
   Google Scholar
• A study of pegylated rhG-CSF as support to advanced non-small-cell lung cancer (NSCLC) patients receiving chemotherapy receiving chemotherapy. Available from: https://clinicaltrials.gov/ct2/show/NCT01560195
   Google Scholar
• Circulating miRNAs as biomarkers of hormone sensitivity in breast cancer (MIRHO). Available from: https://clinicaltrials.gov/ct2/show/NCT01612871
   Google Scholar
• REBECCA study (RadiothErapy for BrEast Cancer and CArdiotoxicity). Available from: https://clinicaltrials.gov/ct2/show/NCT02079272
   Google Scholar
• An Exercise RCT targeting african-american women with metabolic syndrome and high risk for breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02103140
   Google Scholar
• CPCT-05 biopsy protocol patient selection. Available from: https://clinicaltrials.gov/ct2/show/NCT01904916
   Google Scholar